Journal of Advances in Leukemia

 

Journal Advances in Leukaemia is a leading Open Access & Peer-Reviewed publication committed to advancing the field of leukemia research. Our mission is to provide high-quality research and insights to a global audience, serving as a trusted resource in this critical domain.

 

Our journal is dedicated to pioneering research in leukemia, covering topics such as leukemia causes, symptoms, diagnosis, treatment, and the latest advancements in understanding and combating this disease.

 

We focus on providing insights into the most recent discoveries and developments in leukemia research, benefiting healthcare professionals, researchers, and patients seeking the latest treatment options. Our content emphasizes the clinical application of leukemia research, making it invaluable for healthcare professionals, oncologists, and researchers who aim to improve patient care and treatment outcomes.

 

Review: 09 days from the submission time.

Submission to a final decision: 12 days

Acceptance to publication: 3 days

 

Indexing: The articles appear in a wide range of abstracting and indexing databases, and are covered by numerous other services that aid discovery and access.

 

Article Processing Charges: JAL is a self-supporting journal and does not receive funding from any institution/government. Hence, the operation of the journal is supported by the processing fees received from authors.

 

Types of Manuscript submissions: The author can choose any of the following submission types.

 

 

 

 

Revelation: OpenAccess is a great way to connect scientists and the public. It is not only beneficial to the public, but also to scientists who publish because the more people know and discuss scientific finds, the greater its impact becomes.

 

Various journals: Do not hesitate to acknowledge us if your research scope varies from the mentioned journal. We have ample journals dealing with various subjects. For your reference, I’m providing the complete journals. 

 

Contact: Editorial inquiries should be directed to [email protected]

 

Thank you for joining us in advance!